Our management and technical teams have many years of drug development experience. Prior to coming together they achieved twelve FDA drug approvals in neuroscience and other areas of clinical medicine. Our expertise represents a cross-section of drug development disciplines, including preclinical development, clinical development, medical affairs, regulatory, pharmaceutical development and supply chain management.
Remi BarbierChairman of the Board, President & CEO
Remi Barbier, the Company’s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors since the Company’s inception in May 1998. Prior to that time, Mr. Barbier helped in the growth or founding of Exelixis Inc. and ArQule, Inc., both publicly-traded drug development companies, and EnzyMed, Inc., a chemistry company sold to Albany Molecular Research, Inc. Mr. Barbier is trustee emeritus of the Carnegie Institute of Washington and the Santa Fe Institute, and is on the Advisory Board of the University of California’s Institute for Quantitative Biosciences and BioVentures LLC, a life science incubator at the University of Arkansas for Medical Sciences.
Nadav Friedmann PhD, MDChief Medical & Operating Officer
Dr. Nadav Friedmann joined SAVA as Chief Medical and Operating Officer in October 2001 and has served as a director since September 1998. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various senior leadership positions with Johnson & Johnson, including Head of its Biotechnology Research Center.
Eric SchoenChief Financial Officer
Eric Schoen has served as SAVA’s Chief Financial Officer since October 2018. Prior to joining the Company, Mr. Schoen served as Vice President, Senior Vice President, Finance and Chief Accounting Officer of Vermillion, Inc., a publicly-traded bioanalytical-based women’s health company focused on gynecologic disease, from 2011 to 2017. Mr. Schoen also began his career and spent nine years with PricewaterhouseCoopers in the audit and assurance, transaction services and global capital markets practices.
Lindsay H. Burns PhDSVP, Neuroscience
Lindsay H. Burns, PhD has been the lead scientist on Cassava Sciences’ Alzheimer’s disease program since she and Dr. Hoau-Yan Wang discovered PTI-125’s novel target. Dr. Burns has led the program through medicinal chemistry, lead profiling and IND-enabling studies to its current stage of clinical trials in Alzheimer’s disease patients. Trained in neuropsychology at the University of Cambridge and Harvard College, Dr. Burns has a broad background in neuroscience and neurodegenerative disease that spans functional in vitro assays, preclinical models of disease and cognitive/behavioral testing.
Michael ZamlootSr. VP, Tech. Operations
Mike Zamloot has 35 years of pharmaceutical industry experience with multinational firms and development stage biopharmaceutical companies. He has held his current position with Cassava Sciences since 2000, and has responsibility for all aspects of Pharmaceutical Development, Quality and Supply Chain Management. Mike holds a BS degree in Chemical Engineering with honors from the New Jersey Institute of Technology and is an inventor on more than 25 patents.
George (Ben) Thornton PhDSr. VP, Technology
Ben Thornton has over 30 years experience in leading research and development teams in large pharma (Johnson & Johnson) and start up biotechnology companies (GeneMedicine, Apovia) translating basic science to the clinical setting. He has held his current position with Cassava Sciences since 2005. Ben holds a PhD in Molecular Biology from the University of Texas M.D. Anderson School of Biomedical Sciences and was a post-doctoral fellow at the Roche Institute of Molecular Biology. He is currently a Trustee of The Torrey Pines Institute for Molecular Sciences.